|
1
|
Ward EM, Sherman RL, Henley SJ, Jemal A,
Siegal DA, Feuer EJ, Firth AU, Kohler BA, Scott S, et al: Annual
report to the nation on the status of cancer, featuring cancer in
men and women age 20–49 years. J Natl Cancer Inst. 111:2723–1297.
2019. View Article : Google Scholar
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huk DJ, Ashtekar A, Magner A, La Perle K
and Kirschner LS: Deletion of Rap1b, but not Rap1a or Epac1,
reduces protein kinase A-mediated thyroid cancer. Thyroid.
28:1153–1161. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luzon-Toro B, Fernandez RM,
Villalba-Benito L, Torroglosa A, Antinolo G and Borrego S:
Influencers on thyroid cancer onset: Molecular genetic basis. Genes
(Basel). 10:9132019. View Article : Google Scholar
|
|
6
|
Tella SH, Kommalapati A, Esquivel MA and
Correa R: Potential role of metabolic intervention in the
management of advanced differentiated thyroid cancer. Front Oncol.
7:1602017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma Y and Sun Y: miR-29a-3p inhibits
growth, proliferation, and invasion of papillary thyroid carcinoma
by suppressing NF-κB signaling via direct targeting of OTUB2.
Cancer Manag Res. 11:13–23. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McKenna LB, Schug J, Vourekas A, McKenna
JB, Bramswig NC, Friedman JR and Kaestner KH: MicroRNAs control
intestinal epithelial differentiation, architecture, and barrier
function. Gastroenterology. 139:1654–1664. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wojtas B, Ferraz C, Stokowy T, Hauptmann
S, Lange D, Dralle H, Musholt T, Jarzab B, Paschke R and Eszlinger
M: Differential miRNA expression defines migration and reduced
apoptosis in follicular thyroid carcinomas. Mol Cell Endocrinol.
388:1–9. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ling H, Fabbri M and Calin GA: MicroRNAs
and other non-coding RNAs as targets for anticancer drug
development. Nat Rev Drug Discov. 12:847–865. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takahashi RU, Prieto-Vila M, Hironaka A
and Ochiya T: The role of extracellular vesicle microRNAs in cancer
biology. Clin Chem Lab Med. 55:648–656. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao XB, Chen CL, Tian ZL, Yuan FK and Jia
GL: MicroRNA-791 is an independent prognostic factor of papillary
thyroid carcinoma and inhibits the proliferation of PTC cells. Eur
Rev Med Pharmacol Sci. 22:5562–5568. 2018.PubMed/NCBI
|
|
14
|
Mishra S, Yadav T and Rani V: Exploring
miRNA based approaches in cancer diagnostics and therapeutics. Crit
Rev Oncol Hematol. 98:12–23. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao C, Li Y, Chen G, Wang F, Shen Z and
Zhou R: Overexpression of miR-15b-5p promotes gastric cancer
metastasis by regulating PAQR3. Oncol Rep. 38:352–358. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rissland OS, Hong SJ and Bartel DP:
MicroRNA destabilization enables dynamic regulation of the miR-16
family in response to cell-cycle changes. Mol Cell. 43:993–1004.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dong Y, Zhang N, Zhao S, Chen X, Li F and
Tao X: miR-221-3p and miR-15b-5p promote cell proliferation and
invasion by targeting Axin2 in liver cancer. Oncol Lett.
18:6491–6500. 2019.PubMed/NCBI
|
|
18
|
Chava S, Reynolds PC, Pathania AS,
Gorantla S, Poluektova LY, Coulter DW, Gupta SC, Pandey MK and
Challagundla KB: miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit
tumor progression by directly targeting MYCN in neuroblastoma. Mol
Oncol. 14:180–196. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pan WY, Zeng JH, Wen DY, Wang JY, Wang PP,
Chen G and Feng ZB: Oncogenic value of microRNA-15b-5p in
hepatocellular carcinoma and a bioinformatics investigation. Oncol
Lett. 17:1695–1713. 2019.PubMed/NCBI
|
|
20
|
Li H, Zhang J, Lee MJ, Yu GR, Han X and
Kim DG: OIP5, a target of miR-15b-5p, regulates hepatocellular
carcinoma growth and metastasis through the AKT/mTORC1 and
b-catenin signaling pathways. Oncotarget. 8:18129–18144. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang Y, Hou N, Wang X, Wang L, Chang S, He
K, Zhao Z, Zhao X, Song T and Huang C: miR-15b-5p induces
endoplasmic reticulum stress and apoptosis in human hepatocellular
carcinoma, both in vitro and in vivo, by suppressing Rab1A.
Oncotarget. 6:16227–16238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Y, Chen J, Liu Y, Li S and Huang P:
Plasma miR-15b-5p, miR-338-5p, and miR-764 as biomarkers for
hepatocellular carcinoma. Med Sci Monit. 21:1864–1871. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen R, Sheng L, Zhang HJ, Ji M and Qian
WQ: miR-15b-5p facilitates the tumorigenicity by targeting RECK and
predicts tumour recurrence in prostate cancer. J Cell Mol Med.
22:1855–1863. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Theodorescu D, Sapinoso LM, Conaway MR,
Oxford G, Hampton GM and Frierson HF Jr: Reduced expression of
metastasis suppressor RhoGDI2 is associated with decreased survival
for patients with bladder cancer. Clin Cancer Res. 10:3800–3806.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alcántara-Hernández R, Casas-González P
and García-Sáinz JA: Roles of c-Src in alpha1B-adrenoceptor
phosphorylation and desensitization. Auton Autacoid Pharmacol.
28:29–39. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun ZL, Zhu Y, Wang FQ, Chen R, Peng T,
Fan ZN, Xu ZK and Miao Y: Serum proteomic-based analysis of
pancreatic carcinoma for the identification of potential cancer
biomarkers. Biochim Biophys Acta. 1774:764–771. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang XY, Hong SS, Zhang M, Cai QQ, Zhang
MX and Xu CJ: Proteomic alterations of fibroblasts induced by
ovarian cancer cells reveal potential cancer targets. Neoplasma.
65:104–112. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bai Z, Ye Y, Liang B, Xu F, Zhang H, Zhang
Y, Peng J, Shen D, Cui Z, Zhang Z and Wang S: Proteomics-based
identification of a group of apoptosis-related proteins and
biomarkers in gastric cancer. Int J Oncol. 38:375–383.
2011.PubMed/NCBI
|
|
29
|
Lee DH, Chung K, Song JA, Kim TH, Kang H,
Huh JH, Jung SG, Ko JJ and An HJ: Proteomic identification of
paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in
human ovarian cancer cells. J Proteome Res. 9:5668–5676. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kashyap MK, Harsha HC, Renuse S, Pawar H,
Sahasrabuddhe NA, Kim MS, Marimuthu A, Keerthikumar S, Muthusamy B,
Kandasamy K, et al: SILAC-based quantitative proteomic approach to
identify potential biomarkers from the esophageal squamous cell
carcinoma secretome. Cancer Biol Ther. 10:796–810. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Onda M, Emi M, Yoshida A, Miyamoto S,
Akaishi J, Asaka S, Mizutani K, Shimizu K, Nagahama M, Ito K, et
al: Comprehensive gene expression profiling of anaplastic thyroid
cancers with cDNA microarray of 25 344 genes. Endocr Relat Cancer.
11:843–854. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lubitz CC, Zhan T, Gunda V, Amin S,
Gigliotti BJ, Fingeret AL, Holm TM, Wachtel H, Sadow PM, Wirth LJ,
et al: Circulating BRAF(V600E) Levels Correlate with Treatment in
Patients with Thyroid Carcinoma. Thyroid. 28:328–339. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wei WJ, Zhang GQ and Luo QY: Postsurgical
management of differentiated thyroid cancer in China. Trends
Endocrinol Metab. 29:71–73. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fu G, Polyakova O, MacMillan C, Ralhan R
and Walfish PG: Programmed death-ligand 1 expression distinguishes
invasive encapsulated follicular variant of papillary thyroid
carcinoma from noninvasive follicular thyroid neoplasm with
papillary-like nuclear features. EBioMedicine. 18:50–55. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin P, He Y, Wen DY, Li XJ, Zeng JJ, Mo
WJ, Li Q, Peng JB, Wu YQ, Pan DH, et al: Comprehensive analysis of
the clinical significance and prospective molecular mechanisms of
differentially expressed autophagy-related genes in thyroid cancer.
Int J Oncol. 53:603–619. 2018.PubMed/NCBI
|
|
37
|
Gao RZ, Que Q, Lin P, Pang YY, Wu HY, Li
XJ, Chen G, He Y and Yang H: Clinical roles of miR-136-5p and its
target metadherin in thyroid carcinoma. Am J Transl Res.
11:6754–6774. 2019.PubMed/NCBI
|
|
38
|
Wu YC, Li SY and Jia YF: MicroRNA-26a
suppresses the malignant biological behaviors of papillary thyroid
carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling
pathway. Eur Rev Med Pharmacol Sci. 23:8940–8949. 2019.PubMed/NCBI
|
|
39
|
Liu F, Lou K, Zhao X, Zhang J, Chen W,
Qian Y, Zhao Y, Zhu Y and Zhang Y: miR-214 regulates papillary
thyroid carcinoma cell proliferation and metastasis by targeting
PSMD10. Int J Mol Med. 42:3027–3036. 2018.PubMed/NCBI
|
|
40
|
Fu YT, Zheng HB, Zhang DQ, Zhou L and Sun
H: MicroRNA-1266 suppresses papillary thyroid carcinoma cell
metastasis and growth via targeting FGFR2. Eur Rev Med Pharmacol
Sci. 22:3430–3438. 2018.PubMed/NCBI
|
|
41
|
Salimi S, Noorbakhsh F, Faghihzadeh S,
Ghaffarpour S and Ghazanfari T: Expression of miR-15b-5p,
miR-21-5p, and SMAD7 in lung tissue of sulfur mustard-exposed
individuals with long-term pulmonary complications. Iran J Allergy
Asthma Immunol. 18:332–339. 2019.PubMed/NCBI
|
|
42
|
Luo H, Li Y, Liu B, Yang Y and Xu ZD:
MicroRNA-15b-5p targets ERK1 to regulate proliferation and
apoptosis in rat PC12 cells. Biomed Pharmacother. 92:1023–1029.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ahmad P, Sana J, Slavik M, Gurin D, Radova
L, Gablo NA, Kazda T, Smilek P, Horakova Z, Gal B, et al:
MicroRNA-15b-5p predicts locoregional relapse in head and neck
carcinoma patients treated with intensity-modulated radiotherapy.
Cancer Genomics Proteomics. 16:139–146. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Weng Y, Shen Y, He Y, Pan X, Xu J, Jiang
Y, Zhang Q, Wang S, Kong F, Zhao S, et al: The miR-15b-5p/PDK4 axis
regulates osteosarcoma proliferation through modulation of the
Warburg effect. Biochem Biophys Res Commun. 503:2749–2757. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhao C, Zhao Q, Zhang C, Wang G, Yao Y,
Huang X, Zhan F, Zhu Y, Shi J, Chen J, et al: miR-15b-5p
resensitizes colon cancer cells to 5-fluorouracil by promoting
apoptosis via the NF-κB/XIAP axis. Sci Rep. 7:41942017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jin X, Chen Y, Chen H, Fei S, Chen D, Cai
X, Liu L, Lin B, Su H, Zhao L, et al: Evaluation of tumor-derived
exosomal miRNA as potential diagnostic biomarkers for early-stage
non-small cell lung cancer using next-generation sequencing. Clin
Cancer Res. 23:5311–5319. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gu M: IL13Ralpha2 siRNA inhibited cell
proliferation, induced cell apoptosis, and suppressed cell invasion
in papillary thyroid carcinoma cells. Onco Targets Ther.
11:1345–1352. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Huang LL, Wang Z, Cao CJ, Ke ZF, Wang F,
Wang R, Luo CQ, Lu X and Wang LT: AEG-1 associates with metastasis
in papillary thyroid cancer through upregulation of MMP2/9. Int J
Oncol. 51:812–822. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu ZM, Wu ZY, Li WH, Wang LQ, Wan JN and
Zhong Y: MiR-96-5p promotes the proliferation, invasion and
metastasis of papillary thyroid carcinoma through down-regulating
CCDC67. Eur Rev Med Pharmacol Sci. 23:3421–3430. 2019.PubMed/NCBI
|
